Search results
Results from the WOW.Com Content Network
The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a ...
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [2] [3] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [ 4 ]
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, [2] the Sinopharm COVID-19 vaccine, [3] or BIBP vaccine, [3][4][5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm 's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, [6] resulting in the two ...
The Philippines is set to sign a supply agreement for AstraZeneca's potential COVID-19 vaccine on Friday, the first such deal in a country aiming to further reopen its economy that has been ...
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
EuBiologics Co., Ltd started the study on February 23, 2021. [6] The study is titled "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults" [6] As of April 26, 2021, the trial is ongoing, and participants are being accepted. It has an expected primary completion date of March 2022.
The facility set a goal of supplying COVID‑19 vaccines to nearly 100 low-to-middle income countries that could not afford them. COVAX sought to fundraise US$6.8 billion to purchase and deliver vaccines to participating countries in proportion to their populations. [32]
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in ...